Fragment-based NMR screening in lead discovery

Structure-Based Drug Discovery

Volumn , Issue , 2007, Pages 73-98

  Lepre, Christopher A ^a   Moore, Jonathan M ^a  

^a VERTEX PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 35348903356     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/1-4020-4407-0_4     Document Type: Chapter

References (62)

1. Becattini B., Sareth S., Zhai D., Crowell K. J., Leone M., Reed J. C. and Pellecchia M. 2004. Targeting apoptosis via chemical design: inhibition of bid-induced cell death by small organic molecules. Chem. Biol. 11, 1107-1117.
2. Boehm H. J., Boehringer M., Bur D., Gmuender H., Huber W., Klaus W., Kostrewa D., Kuehne H., Luebbers T., Meunier-Keller N. et al. 2000. Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening. J. Med. Chem. 43, 2664-2674.
3. Carr R. and Jhoti H. 2002. Structure-based screening of low-affinity compounds. Drug Discovery Today 7, 522-527.
4. Claasen B., Axmann M., Meinecke R. and Meyer B. 2005. Direct observation of ligand binding to membrane proteins in living cells by a saturation transfer double difference (STDD) NMR spectroscopy method shows a significantly higher affinity of integrin alpha (IIb) beta3 in native platelets than in liposomes. J. Am. Chem. Soc. 127, 916-919.
5. Dalvit C., Fogliatto G., Stewart A., Veronesi M. and Stockman B. 2001. WaterLOGSY as a method for primary NMR screening: practical aspects and range of applicability. J. Biomol. NMR 21, 349-359.
6. Dalvit C., Pevarello P., Tato M., Veronesi M., Vulpetti A. and Sundstrom M. 2000. Identification of compounds with binding affinity to proteins via magnetization transfer from bulk water. J. Biomol. NMR 18, 65-68.
7. Fejzo J., Lepre C. A., Peng J. W., Bemis G. W., Ajay, Murcko M. A. and Moore J. M. 1999. The SHAPES strategy: An NMR-based approach for lead generation in drug discovery. Chem. Biol. 6, 755-769.
8. Fejzo J., Lepre C. and Xie X. 2002. Applications of NMR screening in drug discovery. Curr. Top. Med. Chem. 2, 1349-1364.
9. Hajduk P. J., Augeri D. J., Mack J., Mendoza R., Yang J., Betz S. F. and Fesik S. W. 2000a. NMR-based screening of proteins containing 13C-labeled methyl groups. J. Am. Chem. Soc. 122, 7898-7904.
10. Hajduk P. J., Boyd S., Nettesheim D., Nienaber V., Severin J., Smith R., Davidson D., Rockway T. and Fesik S. W. 2000b. Identification of novel inhibitors of urokinase via NMR-based screening. J. Med. Chem. 43, 3862-3866.
11. Hajduk P. J., Dinges J., Schkeryantz J. M., Janowick D., Kaminski M., Tufano M., Augeri D. J., Petros A., Nienaber V., Zhong P. et al. 1999a. Novel inhibitors of erm methyltransferases from NMR and parallel synthesis. J. Med. Chem. 42, 3852-3859.
12. Hajduk P. J., Gerfin T., Boehlen J.-M., Haberli M., Marek D. and Fesik S. W. 1999b. High-throughput nuclear magnetic resonance-based screening. J. Med. Chem. 42, 2525-2517.
13. Hajduk P. J., Gomtsyan A., Didomenico S., Cowart M., Bayburt E. K., Solomon L., Severin J., Smith R., Walter K., Holzman T. F. et al. 2000c. Design of adenosine kinase inhibitors from the NMR-based screening of fragments. J. Med. Chem. 43, 4781-4786.
14. Hajduk P. J., Meadows R. P. and Fesik S. J. 1999c. NMR-based screening in drug discovery. Q. Rev. Biophys. 32, 211-240.
15. Huth J. R. and Sun C. 2002. Utility of NMR in lead optimization: fragment-based approaches. Comb. Chem. High Throughput Screen. 5, 631-643.
16. Hwang T.-L. and Shaka A. J. 1995. Water suppression that works. excitation sculpting using arbitrary waveforms and pulsed field gradients. J. Magn. Reson. Ser. A 112, 275-279.
17. Jahnke W., Blommers M. J., Fernandez C., Zwingelstein C. and Amstutz R. 2005. Strategies for the NMR-Based identification and optimization of allosteric protein kinase inhibitors. Chembiochem. 6, 1607-1610.
18. Jahnke W., Floersheim P., Ostermeier C., Zhang X., Hemmig R., Hurth K. and Uzunov D. P. 2002. NMR reporter screening for the detection of high-affinity ligands. Angew. Chem. Int. Ed. Engl. 41, 3420-3423.
19. Jahnke W., Florsheimer A., Blommers M. J., Paris C. G., Heim J., Nalin C. M. and Perez L. B. 2003. Second-site NMR screening and linker design. Curr. Top. Med. Chem. 3, 69-80.
20. Jahnke W., Perez L. B., Paris G., Strauss A., Fendrich G. and Nalin C. M. 2000. Second-Site NMR Screening with a Spin-Labeled First Ligand. J. Am. Chem. Soc. 122, 7394-7395.
21. Jahnke W., Rudisser S. and Zurini M. 2001. Spin label enhanced NMR screening. J. Am. Chem. Soc. 123, 3149-3150.
22. Johnson E. C., Feher V. A., Peng J. W., Moore J. M. and Williamson J. R. 2003. Application of NMR SHAPES screening to an RNA target. J. Am. Chem. Soc. 125, 15724-15725.
23. Klaus W. and Senn H. 2003. Strategies for hit finding using NMR. In BioNMR in Drug Research, O. Zerbe, ed. (Weinheim, Wiley-VCH) pp. 417-437.
24. Klein J., Meinecke R., Mayer M. and Meyer B. 1999. Detecting binding affinity to immobilized receptor proteins in compound libraries by HR-MAS STD NMR. J. Am. Chem. Soc. 121, 5336-5337.
25. Lepre C. A. 2001. Library design for NMR-based screening. Drug Discovery Today 6, 133-140.
26. Lepre C. A. 2002. Strategies for NMR screening and library design. In BioNMR Techniques in Drug Research, O. Zerbe, ed. (Weinheim, Wiley-VCH) pp. 1349-1364.
27. Lepre C. A., Moore J. M. and Peng J. W. 2004. Theory and applications of NMR-based screening in pharmaceutical research. Chem. Rev. 104, 3641-3676.
28. Lepre C. A., Peng J., Fejzo J., Abdul-Manan N., Pocas J., Jacobs M., Xie X. and Moore J. M. 2002. Applications of SHAPES screening in drug discovery. Comb. Chem. High Throughput Screen. 5, 583-590.
29. Lesuisse D., Lange G., Deprez P., Benard D., Schoot B., Delettre G., Marquette J. P., Broto P., Jean-Baptiste V., Bichet P. et al. 2002. SAR and X-ray. A new approach combining fragment-based screening and rational drug design: Application to the discovery of nanomolar inhibitors of Src SH2. J. Med. Chem. 45, 2379-2387.
30. Li D., De Rose E. F. and London R. E. 1999. The inter-ligand overhauser effect: A powerful new NMR approach for mapping structural relationships of macromolecular ligands. J. Biomol. NMR 15, 71-76.
31. Liepinsh E. and Otting G. 1997. Organic solvents identify specific ligand binding sites on protein surfaces. Nat. Biotechnol. 15, 264-268.
32. Lipinski C. A., Lombardo F., Dominy B. W. and Feeny P. J. 1997. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23, 3-25.
33. Liu G., Szczepankiewicz B. G., Pei Z., Janowick D. A., Xin Z., Hajduk P. J., Abad-Zapatero C., Liang H., Hutchins C. W., Fesik S. W. et al. 2003a. Discovery and structure-activity relationship of oxalylarylaminobenzoic acids as inhibitors of protein tyrosine phosphatase 1B. J. Med. Chem. 46, 2093-2103.
34. Liu G., Xin Z., Liang H., Abad-Zapatero C., Hajduk P. J., Janowick D. A., Szczepankiewicz B. G., Pei Z., Hutchins C. W., Ballaron S. J. et al. 2003b. Selective protein tyrosine phosphatase 1B inhibitors: Targeting the second phosphotyrosine binding site with non-carboxylic acid-containing ligands. J. Med. Chem. 46, 3437-3440.
35. Liu G., Xin Z., Pei Z., Hajduk P. J., Abad-Zapatero C., Hutchins C. W., Zhao H., Lubben T. H., Ballaron S. J., Haasch D. L. et al. 2003c. Fragment screening and assembly: A highly efficient approach to a selective and cell active protein tyrosine phosphatase 1B inhibitor. J. Med. Chem. 46, 4232-4235.
36. Lugovskoy A. A., Degterev A. I., Fahmy A. F., Zhou P., Gross J. D., Yuan J. and Wagner G. 2002. A novel approach for characterizing protein ligand complexes: Molecular basis for specificity of small-molecule Bcl-2 inhibitors. J. Am. Chem. Soc. 124, 1234-1240.
37. Mayer M. and Meyer B. 1999. Characterization of ligand binding by saturation transfer difference NMR spectroscopy. Angew. Chem. Int. Ed. 38, 1784-1788.
38. McCoy M. A., Senior M. M. and Wyss D. F. 2005. Screening of protein kinases by ATP-STD NMR spectroscopy. J. Am. Chem. Soc. 127, 7978-7979.
39. McCoy M. A. and Wyss D. F. 2000. Alignment of weakly interacting molecules to protein surfaces using simulations of chemical shift perturbations. J. Biomol. NMR 18, 189-198.
40. McCoy M. A. and Wyss D. F. 2002. Spatial localization of ligand binding sites from electron current density surfaces calculated from NMR chemical shift perturbations. J. Am. Chem. Soc. 124, 11758-11763.
41. Medek A., Hajduk P. J., Mack J. and Fesik S. W. 2000. The use of differential chemical shifts for determining the binding site location and orientation of protein-bound ligands. J. Am. Chem. Soc. 122, 1241-1242.
42. Meinecke R. and Meyer B. 2001. Determination of the binding specificity of an integral membrne protein by saturation transfer difference NMR: RGD peptide ligands binding to integrin aIIbb3. J. Am. Chem. Soc. 44, 3059-3065.
43. Moore J. M. 1999. NMR screening in drug discovery. Curr. Opin. Biotechnol. 10, 54-58.
44. Nienaber V. L., Richardson P. L., Klighofer V., Bouska J. J., Giranda V. L. and Greer J. 2000. Discovering novel ligands for macromolecules using X-ray crystallographic screening. Nat. Biotechnol. 18, 1105-1108.
45. Oltersdorf T., Elmore S. W., Shoemaker A. R., Armstrong R. C., Augeri D. J., Belli B. A., Bruncko M., Deckwerth T. L., Dinges J., Hajduk P. J. et al. 2005. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435, 677-681.
46. Park C. M., Sun C., Olejniczak E. T., Wilson A. E., Meadows R. P., Betz S. F., Elmore S. W. and Fesik S. W. 2005. Non-peptidic small molecule inhibitors of XIAP. Bioorg. Med. Chem. Lett. 15, 771-775.
47. Pellecchia M., Meininger D., Dong Q., Chang E., Jack R. and Sem D. S. 2002a. NMR-based structural characterization of large protein-ligand interactions. J. Biomol. NMR 22, 165-173.
48. Pellecchia M., Sem D. S. and Wuthrich K. 2002b. NMR in drug discovery. Nature Rev. Drug Discov. 1, 211-219.
49. Peng J. W., Moore J. and Abdul-Manan N. 2004. NMR Experiments for lead generation in drug discovery. Prog. Nucl. Magn. Reson. Spectrosc. 44, 225-256.
50. Peng J. W., Lepre C. A., Fejzo J., Abdul-Manan N. and Moore J. M. 2001. Nuclear magnetic resonance-based approaches for lead generation in drug discovery. Methods Enzymol. 338, 202-230.
51. Roberts G. C. 2000. Applications of NMR in drug discovery. Drug Discovery Today 5, 230-240.
52. Ross A., Schlotterbeck G., Klaus W. and Senn H. 2000. Automation of NMR measurements and data evaluation for systematically screening interactions of small molecules with target proteins. J. Biomol. NMR 16, 139-146.
53. Ross A. and Senn H. 2001. Automation of measurements and data evaluation in biomolecular NMR screening. Drug Discovery Today 6, 583-593.
54. Rudisser S. and Jahnke W. 2002. NMR and in silico screening. Comb. Chem. High Throughput Screen. 5, 591-603.
55. Shuker S. B., Hajduk P. J., Meadows R. P. and Fesik S. W. 1996. Discovering highaffinity ligands for proteins: SAR by NMR. Science 274, 1531-1534.
56. Stockman B. and Dalvit C. 2002. NMR screening techniques in drug discovery and drug design. Prog. Nucl. Magn. Reson. Spectrosc. 41, 187-231.
57. Szczepankiewicz B. G., Liu G., Hajduk P. J., Abad-Zapatero C., Pei Z., Xin Z., Lubben T. H., Trevillyan J. M., Stashko M. A., Ballaron S. J. et al. 2003. Discovery of a potent, selective protein tyrosine phosphatase 1B inhibitor using a linked-fragment strategy. J. Am. Chem. Soc. 125, 4087-4096.
58. Teague S. J., Davis A. M., Leeson P. D. and Oprea T. 1999. The design of leadlike combinatorial libraries. Angew. Chem. Int. Ed. 38, 3743-3747.
59. Van Dongen M., Uppenberg J., Svensson B., Lundbäck T., Åkerud T., Wikström M. and Schultz J. 2002a. Structure-based screening as applied to human FABP4: A highly efficient alternative to HTS for hit generation. J. Am. Chem. Soc. 124, 11874-11880.
60. Van Dongen M., Weigelt J., Uppenberg J., Schultz J. and Wikstrom M. 2002b. Structurebased screening and design in drug discovery. Drug Discovery Today 7, 471-478.
61. Wyss D. F., Arasappan A., Senior M. M., Wang Y.-S., Beyer B. M., Njoroge F. G. and McCoy M. A. 2004. Non-peptidic small molecule inhibitors of the single-chain hepatitic C virus NS3 protease NS4A cofactor complex discovered by structure-based NMR screening. J. Med. Chem. 47, 2486-2498.
62. Wyss D. F., McCoy M. A. and Senior M. M. 2002. NMR-based approaches for lead discovery. Curr. Opin. Drug Discov. Devel. 5, 630-647.